Opportunity Information: Apply for PAR 23 249
The Alcohol Treatment, Pharmacotherapy, and Recovery Research funding opportunity (PAR-23-249) is a National Institutes of Health grant run by the National Institute on Alcohol Abuse and Alcoholism (NIAAA) that supports alcohol health services research aimed at closing the treatment gap for people with alcohol use disorder (AUD). In practical terms, the opportunity is looking for projects that can help more people with AUD get into care, stay in care, and benefit from care, especially in real-world settings where access barriers, cost issues, stigma, and uneven quality of services often limit impact. The award uses the R34 mechanism, which is typically used to support early-stage clinical trial-related work such as pilot testing, feasibility studies, refinement of protocols, and other preparatory steps needed to move an intervention toward a larger, fully powered trial or broader implementation.
The notice of funding opportunity highlights five main research emphasis areas. First, it prioritizes studies designed to increase access to treatment for AUD. That can include service delivery models that expand where and how treatment is offered, such as integrating AUD care into primary care, emergency departments, mental health clinics, telehealth, mobile health, or community-based settings, as well as strategies that reduce logistical barriers like transportation, scheduling, childcare needs, or limited provider availability. Second, it encourages work that makes AUD treatment more appealing, which generally means reducing stigma and friction in the treatment experience and aligning services with patient preferences. Projects in this area might focus on patient-centered engagement approaches, lowering the threshold to start care, improving retention, tailoring care pathways, or testing messaging and outreach strategies that motivate people to consider treatment earlier.
Third, NIAAA is explicitly interested in the cost side of the treatment gap, including cost structures and insurance systems that shape whether care is reachable and sustainable. This can involve analyzing reimbursement policies, benefit design, prior authorization, provider incentives, and out-of-pocket costs, along with how these factors affect adoption of evidence-based AUD services. Fourth, the opportunity emphasizes dissemination and implementation research focused on getting existing evidence-based AUD treatments used more consistently and effectively in everyday practice. Rather than inventing new interventions from scratch, this area often focuses on identifying barriers and facilitators to adoption, testing implementation strategies (for example, training models, decision support, workflow redesign, audit-and-feedback, or measurement-based care), and evaluating fidelity, reach, and sustainability in routine care systems.
Fifth, and woven throughout the entire NOFO, is a strong emphasis on reducing health disparities in AUD treatment as a direct way to close the overall treatment gap. The intent is to support research that improves access and outcomes for health disparity populations and addresses structural and contextual factors that contribute to unequal treatment availability, quality, and engagement. Projects may focus on culturally responsive care models, inequities in service distribution, differences in insurance coverage or treatment quality, and implementation approaches that are designed from the start to work well in underserved communities.
In terms of who can apply, eligibility is broad and includes many types of public and private organizations. Eligible applicants include state, county, and local governments; special districts; independent school districts; public housing authorities; federally recognized tribal governments and other tribal organizations; public and private institutions of higher education; nonprofit organizations (both with and without 501(c)(3) status); for-profit organizations (other than small businesses); and small businesses. The NOFO also explicitly calls out additional eligible groups such as Historically Black Colleges and Universities, Hispanic-serving Institutions, Tribally Controlled Colleges and Universities, Alaska Native and Native Hawaiian Serving Institutions, and Asian American Native American Pacific Islander Serving Institutions, as well as faith-based or community-based organizations, eligible federal agencies, U.S. territories or possessions, regional organizations, and even non-U.S. (foreign) entities.
Administratively, this is a discretionary grant in the health category (CFDA 93.273). The listed award ceiling is $450,000. The opportunity was created on August 9, 2023, and the original closing date is September 7, 2026. Overall, the program is essentially a call for rigorous, practice-relevant research that can remove real barriers to AUD care, improve uptake of evidence-based treatment and pharmacotherapy, and build workable paths to recovery support, with particular attention to implementation in real systems and to equity-focused outcomes.Apply for PAR 23 249
- The National Institutes of Health in the health sector is offering a public funding opportunity titled "Alcohol Treatment, Pharmacotherapy, and Recovery Research (R34 Clinical Trial required)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.273.
- This funding opportunity was created on 2023-08-09.
- Applicants must submit their applications by 2026-09-07. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Each selected applicant is eligible to receive up to $450,000.00 in funding.
- Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Browse more opportunities from the same category: Health
Next opportunity: Wood Utilization Assistance
Previous opportunity: Cooperative Agreement for CESU-affiliated Partner with Chesapeake Cooperative Ecosystem Studies Unit
Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PAR 23 249
Applicants also applied for:
Applicants who have applied for this opportunity (PAR 23 249) also looked into and applied for these:
| Funding Opportunity |
|---|
| Community-Engaged Health Equity Research in Neuroscience Initiative (R01 CT Not Allowed) Apply for RFA NS 24 006 Funding Number: RFA NS 24 006 Agency: National Institutes of Health Category: Health Funding Amount: $500,000 |
| Behavioral and Social Research on the Role of Immigration on Life Course Health and Aging, including AD/ADRD?(R01 Clinical Trial Not Allowed) Apply for RFA AG 24 028 Funding Number: RFA AG 24 028 Agency: National Institutes of Health Category: Health Funding Amount: $500,000 |
| Behavioral and Social Research on the Role of Immigration on Life Course Health and Aging, including AD/ADRD?(R21 Clinical Trial Not Allowed) Apply for RFA AG 24 029 Funding Number: RFA AG 24 029 Agency: National Institutes of Health Category: Health Funding Amount: $275,000 |
| Community-Engaged Health Equity Research in Neuroscience Initiative (R34 CT Not Allowed) Apply for RFA NS 24 007 Funding Number: RFA NS 24 007 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Neural and Non-Neural Mechanisms Underlying Gait as a Preclinical Marker for Alzheimers Disease and Alzheimers Disease-Related Dementias (R01 Clinical Trial Optional) Apply for RFA AG 24 041 Funding Number: RFA AG 24 041 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NIA Research and Entrepreneurial Development Immersion (REDI): Entrepreneurial Small Business Transition Award (R43/R44 Clinical Trial Optional) Apply for RFA AG 24 042 Funding Number: RFA AG 24 042 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Planning for Product Development Strategy (R34 Clinical Trial Not Allowed) Apply for PAR 24 029 Funding Number: PAR 24 029 Agency: National Institutes of Health Category: Health Funding Amount: $225,000 |
| USAID Improved Maternal, Newborn, Child Health, Immunization and Nutrition Activity Apply for 72065623APS00001 Funding Number: 72065623APS00001 Agency: Mozambique USAID-Maputo Category: Health Funding Amount: $92,000,000 |
| Analytical and Clinical Validation of Biomarkers for Alzheimers Disease (AD) and AD-Related Dementias (ADRD)?(U01 Clinical Trial Optional) Apply for PAR 23 258 Funding Number: PAR 23 258 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NIA Research and Entrepreneurial Development Immersion (REDI): Entrepreneurial Small Business Transition Award (R41/R42 Clinical Trial Optional) Apply for RFA AG 24 043 Funding Number: RFA AG 24 043 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| VCID Center Without Walls for Understanding and Leveraging Small Vessel Cerebrovascular Disease Mechanisms in ADRD (R01 - Clinical Trial Not Allowed) Apply for RFA NS 24 027 Funding Number: RFA NS 24 027 Agency: National Institutes of Health Category: Health Funding Amount: $1,000,000 |
| NINDS Clinical Trial Methods in Clinical Neurological Disorders Course (R25 Clinical Trial Not Allowed) Apply for RFA NS 23 030 Funding Number: RFA NS 23 030 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| AHRQ Improving Diagnostic Safety in Ambulatory Care: Strategies and Interventions (R18) Apply for PA 23 290 Funding Number: PA 23 290 Agency: Agency for Health Care Research and Quality Category: Health Funding Amount: $500,000 |
| AHRQ Understanding and Improving Diagnostic Safety in Ambulatory Care: Incidence and Contributing Factors (R01) Apply for PA 23 291 Funding Number: PA 23 291 Agency: Agency for Health Care Research and Quality Category: Health Funding Amount: $500,000 |
| Seamless Early-Stage Clinical Drug Development (Phase 1 to 2a) for Novel therapeutic Agents for the Spectrum of Alzheimer's Disease (AD) and AD-related Dementias (ADRD) (UG3/UH3 Clinical Trial Required) Apply for PAR 23 274 Funding Number: PAR 23 274 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Chimeric Antigen Receptor (CAR) Approaches to AD/ADRD (R61/R33 Clinical Trial Not Allowed) Apply for RFA AG 24 046 Funding Number: RFA AG 24 046 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Improving Choice, Use, and Equitable Implementation of Biomedical HIV Prevention for Women (R34 Clinical Trial Optional) Apply for RFA MH 24 162 Funding Number: RFA MH 24 162 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Building Neuroscience Research Infrastructure for Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) in Africa (UG3/UH3 Clinical Trial Not Allowed) Apply for RFA AG 24 027 Funding Number: RFA AG 24 027 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Community Partnerships to Advance Science for Society (ComPASS): Health Equity Research Hubs (UC2 Clinical Trial Optional) Apply for RFA RM 23 012 Funding Number: RFA RM 23 012 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Broadening Opportunities for Computational Genomics and Data Science Education (UE5 Clinical Trial Not Allowed) Apply for RFA HG 23 002 Funding Number: RFA HG 23 002 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Inside Our Applicants Portal
Access Applicants Portal
- Grants Repository - Access current and historic funding opportunities with ease. Thousands of funding opportunities are published every week. We can help you sort through the database and find the eligible ones to apply for.
- Applicant Video Guides - The grant application process can be challenging to follow. We can help you with intuitive video guides to speed up the process and eliminate errors in submissions.
- Grant Proposal Wizard - We have developed a network of private funding organizations and investors across the United States. We can reach out and submit your proposal to these contacts to maximize your chances of getting the funding you need.
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Learn More
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PAR 23 249", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.
